[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100499569":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":26,"locations":35,"responsibleParty":61,"collaborators":25,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":67,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":25,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":91,"whyStopped":25,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Centre hospitalier de Ville-Evrard, France","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Active transcranial direct current stimulation (active tDCS)","EXPERIMENTAL","The transcranial direct current stimulation (tDCS) with two elecrodes placed over the scalp: the anode over the L DLPFG and the cathode over the left temporo-parietal junction (L TPJ)",[13],"Device: tDCS",{"label":15,"type":16,"description":17,"interventionNames":18},"Sham tDCS","PLACEBO_COMPARATOR","Sham Comparator: sham transcranial direct current stimulation tDCS device allows sham stimulation. tDCS device sham technology allows optimum placebo stimulation via the same stimulation impresssion than active stimulation.\n\nElectrode placement is the same than the active arm",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DEVICE","tDCS","tDCS will be delivered using this electrode montage: anode on the left dosolateral prefrontal cortex (L DLPFC) using F3 EEG landmark and cathode on the left temporoparietal junction (L TPJ) on the middle point between T3 and P3 EEG landmark.\n\nThe stimulation will be delivered at an intensity of 2 milliamps, for 20 minutes, five times a day, with 20 min inter sessions (it will be carried out on 5 consecutive days from Monday to Friday). Each processing day corresponds to a visit of V2, V3, V4, V5 and V6.",[9,15],null,[27,32],{"name":28,"role":29,"phone":30,"phoneExt":25,"email":31},"BOUAZIZ Noomane, MD","CONTACT","01 43 09 32 32","urcve@gmail.com",{"name":33,"role":29,"phone":30,"phoneExt":25,"email":34},"BENCHERIF Youcef, Project manager","y.bencherif@epsve.fr",[36,51],{"facility":37,"status":25,"city":38,"state":25,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Ch Ville Evrard","Neuilly-sur-Marne","93330","France","FR",{"type":43,"coordinates":44},"Point",[45,46],2.54903,48.85373,{"lat":46,"lon":45},[49],{"name":50,"role":29,"phone":25,"phoneExt":25,"email":25},"Dominique Januel, MBBS",{"facility":52,"status":25,"city":38,"state":25,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":53,"geoPoint":55,"contacts":56},"Youcef Bencherif",{"type":43,"coordinates":54},[45,46],{"lat":46,"lon":45},[57],{"name":58,"role":29,"phone":59,"phoneExt":25,"email":60},"Youcef BENCHERIF","0782723674","bencherif.info@gmail.com",{"type":62,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Noomane Bouaziz, MD","Principal Investigator","100499569","impact-of-tdcs-on-cannabis-craving-in-schizophrenia-100499569",false,"NCT05784961","Impact of tDCS on Cannabis Craving in Schizophrenia","Impact of tDCS on Cannabis Craving in Patients With Schizophrenia and Cannabis Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study","tCCS","Inclusion Criteria:\n\n1. Patients (male or female) aged 18-65\n2. Patients with schizophrenia according to DSM 5 criteria with Comorbid diagnosis of \"cannabis use disorder\"\n3. Stabilized patients: total score = 80 at initial PANSS score and = 3 at the following PANSS points:\n\n   * conceptual disorganization\n   * distrust\n   * hallucinatory behaviour\n   * Unusual content of thought\n4. Patients without any other drug or psychotherapeutic treatment for cannabis dependence (\"naive\" patients)\n5. Reported cannabis use greater than three times per week in the past three years\n6. Signed consent to participate in research\n7. Affiliation to a French social security scheme\n8. Patient fluent in the French language\n\nExclusion Criteria:\n\n1. Presence of any other psychiatric disorder, as per DSM-5 criteria.\n2. Pregnancy, possible pregnancy due to lack of contraception, breastfeeding.\n3. Currently active suicidal or self-injurious ideation (suicidal or not)\n4. Patients with Serious medical codition\n5. Other \"moderate\" to \"severe\" addictions, according to DSM 5 criteria (excluding tobacco and coffee).\n6. Contraindications to tDCS (presence of intracranial metal material, intracranial hypertension, etc.).\n7. Subjects already treated by tDCS\n8. Patients under legal guardianship (except under curatorship)\n9. Patients under safeguard of justice","ALL","18 Years","65 Years",{"count":77,"type":78},138,"ESTIMATED","INTERVENTIONAL",[81],"NA","This study aims to evaluate the tDCS's impact on cannabis craving in patients with schizophrenia and cannabis addiction disorder.",[84,85],"Schizophrenia","Cannabis Use Disorder",[87,88,89,90],"cannabis use disorder","schizophrenia","cannabis","craving","NOT_YET_RECRUITING","2024-02-15",{"date":94,"type":95},"2024-02-16","ACTUAL",{"date":97,"type":78},"2024-03-01",{"date":99,"type":78},"2027-06-20",{"name":5,"class":6},2]